Log In
Print
BCIQ
Print
Print this Print this
 

CF-404

  Manage Alerts
Collapse Summary General Information
Company ContraFect Corp.
DescriptionCombination of human mAbs CF-401, which targets Type A; Group 1 influenza; CF-402, which targets Type A; Group 2 influenza; and CF-403, which targets Type B influenza
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationInfluenza virus
Indication DetailsTreat seasonal and pandemic influenza infections
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today